Resistance-modifying agents. 11. Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to α1-acid glycoprotein

Journal of Medicinal Chemistry

Volumn 47, Issue 20, 2004, Pages 4905-4922

  Curtin, Nicola J ^b   Barlow, Hannah C ^a   Bowman, Karen J ^b   Calvert, A Hilary ^b   Davison, Richard ^a   Golding, Bernard T ^a   Huang, Bing ^a   Loughlin, Peter J ^a   Newell, David R ^b   Smith, Peter G ^b   Griffin, Roger J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4,6,8 TETRACHLOROPYRIMIDO[5,4 D]PYRIMIDINE; 2,6 BIS(2' HYDROXYETHYLAMINO) 4,8 BIS(N 3',4' DIMETHOXYBENZYL N METHYLAMINO)PYRIMIDO[5,4 D]PYRIMIDINE; 2,6 BIS(2' HYDROXYPROPYLAMINO) 4,8 BIS(3',4' DIOXYMETHYLENEBENZYLAMINO) PYRIMIDO[5,4 D]PYRIMIDINE; 2,6 BIS(2' HYDROXYPROPYLAMINO) 4,8 BIS(4' METHOXYBENZYLAMINO)PYRIMIDO[5,4 D]PYRIMIDINE; 2,6 BIS(2' HYDROXYPROPYLAMINO) 4,8 BIS(N 3',4' DIMETHOXYBENZYL N METHYLAMINO)PYRIMIDO[5,4 D]PYRIMIDINE; 2,6 BIS(2' HYDROXYPROPYLAMINO) 4,8 BIS(N METHYL N 4' METHOXYBENZYLAMINO) PYRIMIDO[5,4 D]PYRIMIDINE; 2,6 BIS(2' HYDROXYPROPYLAMINO) 4,8 BIS(N METHYLBENZYL N METHYLAMINO)PYRIMIDO[5,4 D]PYRIMIDINE; 2,6 BIS(2' HYDROXYPROPYLAMINO) 4,8 DIBENZYLAMINOPYRIMIDO[5,4 D]PYRIMIDINE; 2,6 BIS(2',3' DIHYDROXYPROPYLAMINO) 4,8 DIPIPERIDINOPYRIMIDO[5,4 D]PYRIMIDINE; 2,6 BIS(DIETHANOLAMINO) 4,8 BIS(3' HYDROXYPIPERIDINO)PYRIMIDO[5,4 D]PYRIMIDINE; 2,6 BIS(DIETHANOLAMINO) 4,8 BIS(3',4' DIOXYMETHYLENEBENZYLAMINO)PYRIMIDO[5, 4 D]PYRIMIDINE; 2,6 BIS(DIETHANOLAMINO) 4,8 BIS(4' CHLOROBENZYLAMINO)PYRIMIDO[5,4 D]PYRIMIDINE; 2,6 BIS(DIETHANOLAMINO) 4,8 BIS(4' METHOXYBENZYLAMINO)PYRIMIDO[5,4 D]PYRIMIDINE; 2,6 BIS(DIETHANOLAMINO) 4,8 BIS(4' TRIFLUOROMETHYLBENZYLAMINO)PYRIMIDO[5,4 D]PYRIMIDINE; 2,6 BIS(DIETHANOLAMINO) 4,8 BIS(N 1,2,3,4 TETRAHYDROISOQUINOLYL) PYRIMIDOPYRIMIDINE; 2,6 BIS(DIETHANOLAMINO) 4,8 BIS(N 4' METHOXYBENZYL N METHYLAMINO) PYRIMIDO[5,4 D]PYRIMIDINE; 2,6 BIS(DIETHANOLAMINO) 4,8 BIS(N BENZYL N METHYLAMINO)PYRIMIDO[5,4 D]PYRIMIDINE; 2,6 BIS(DIETHANOLAMINO) 4,8 BIS[(3',4' DIMETHOXYBENZYL)AMINO]PYRIMIDO[5,4 D]PYRIMIDINE; 2,6 BIS(DIETHANOLAMINO) 4,8 DIBENZYLAMINOPYRIMIDO[5,4 D]PYRIMIDINE; 2,6 BIS(DIETHYLAMINO) 4,8 DIPIPERIDINOPYRIMIDO[5,4 D]PYRIMIDINE; 2,6 BIS[N,N BIS(2' METHOXY)ETHYLAMINO] 4,8 DIPIPERIDINOPYRIMIDO[5,4 D]PYRIMIDINE; 2,6 DICHLORO 4,8 DIBENZYLAMINOPYRIMIDO[5,4 D]PYRIMIDINE; 2,6 DIETHANOLAMINO 4,8 BIS(4' METHOXYBENZYLAMINO)PYRIMIDO[5,4 D]PYRIMIDINE; 2,6 DIETHANOLAMINO 4,8 BIS(N BENZYL N 3',4' DIMETHOXYBENZYLAMINO) PYRIMIDO[5,4 D]PYRIMIDINE; 2,6 DIETHANOLAMINO 4,8 DIBENZYLAMINOPYRIMIDO[5,4 D]PYRIMIDINE; 4,8 BIS(DIETHANOLAMINO) 2,6 DIPIPERIDINOPYRIMIDO[5,4 D]PYRIMIDINE; 4,8 DIBENZYLAMINOPYRIMIDO[5,4 D]PYRIMIDINE; 4,8 DIPIPERIDINOPYRIMIDO[5,4 D]PYRIMIDINE; ALPHA1 GLYCOPROTEIN; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; LEUKEMIA L 1210; MOUSE; NONHUMAN; NUCLEOSIDE TRANSPORT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BIOCHEMISTRY; BIOLOGICAL TRANSPORT; DIPYRIDAMOLE; DRUG RESISTANCE, NEOPLASM; LEUKEMIA L1210; MICE; NUCLEOSIDES; OROSOMUCOID; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE;

EID: 4544234922     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040772w     Document Type: Article

References (45)

1. For part 10, see the following. Smith, P. G.; Thomas, H. D.; Barlow, H. C.; Griffin, R. J.; Golding, B. T.; Calvert, A. H.; Newell, D. R.; Curtin, N. J. In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. Clin. Cancer. Res. 2001, 7, 2105-2113.
2. Peters, G. J.; Jansen, G. Antimetabolites. In Oxford Textbook of Oncology; Souhami, R. L., Tannock, I., Hohenberger, P., Horiot, J.-C., Eds.; Oxford University Press: Oxford, 2002; pp 663-713.
3. Cunningham, D.; Zalcberg, J.; Maroun, J.; James, R.; Clarke, S.; Maughan, T. S.; Vincent, M.; Schulz, J.; Baron, M. G.; Facchini, T. Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer: a review of phase II/III trials. Eur. J. Cancer 2002, 38, 478-486.
4. Van Cutsem, E.; Cunningham, D.; Maroun, J.; Cervantes, A.; Glimelius, B. Raltitrexed: current clinical status and future directions. Ann. Oncol. 2002, 13, 513-522.
5. Hughes, A.; Calvert, P.; Azzabi, A.; Plummer, R.; Johnson, R.; Rusthoven, J.; Griffin, M.; Fishwick, K.; Boddy, AV.; Verrill, M.; Calvert, H. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2002, 20, 3533-3544.
6. Manegold, C.; Aisner, J. Pemetrexed for diffuse malignant pleural mesothelioma. Semin. Oncol. 2002, 29 (Suppl. 5), 30-35.
7. Wagstaff, A. J.; Ibbotson, T.; Goa, K. L. Capecitabine - A review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs 2003, 63, 217-236.
8. Jackman, A. L.; Taylor, G. A.; Calvert, A. H.; Harrap, K. R. Modulation of antimetabolite effects: effects of thymidine on the efficacy of the quinazoline-based thymidylate synthase inhibitor, CB3717. Biochem. Pharmacol. 1984, 33, 3269-3275.
9. Shih, C.; Chen, V. J.; Gossett, L. S.; Gates, S. B.; MacKeller, W. C.; Habeck, L. L.; Shackelford, K. A.; Mendelsohn, L. G.; Soose, D. J.; Patel, V. F.; Andis, S. L.; Bewley, J. R.; Rayl, E. A.; Moroson, B. A.; Beardsley, G. P.; Kohler, W.; Ratnam, M.; Schultz, R. M. LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997, 57, 1116-1123.
10. Jackman, A. L.; Kimbell, R.; Aherne, G. W.; Brunton, L.; Jansen, G.; Stephens, T. C.; Smith, M. N.; Wardleworth, J. M.; Boyle, F. T. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamable, quinazoline-based inhibitor of thymidylate synthase. Clin. Cancer Res. 1997, 3, 911-921.
11. Mendelsohn, L. G.; Shih, C. A.; Schultz, R. M.; Worzalla, J. F. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol. Invest. New Drugs 1996, 14, 287-294.
12. Webber, S.; Bartlett, C. A.; Boritzki, T. J.; Hilliard, J. A.; Howland, E. F.; Johnston, A. L.; Kosa, M.; Margosiak, S. A.; Morse, C. A.; Shetty, B. V. AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Cancer Chemother. Pharmacol. 1996, 37, 509-517.
13. Worzalla, J. F.; Shih, C.; Schultz, R. M. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate LY231514. Anticancer Res. 1998, 18, 3235-3239.
14. Schultz, R. M.; Patel, V. F.; Worzalla, J. F.; Shih, C. A. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate. Anticancer Res. 1999, 19, 437-443.
15. Baldwin, S. A.; Mackey, J. R.; Cass, C. E.; Young, J. D. Nucleoside transporters: Molecular biology and implications for therapeutic development. Mol. Med. Today 1999, 5, 216-224.
16. Yao, S. Y. M.; Ng, A. M. L.; Vickers, M. F.; Sundaram, M.; Cass, C. E.; Baldwin, S. A.; Young, J. D. Functional and molecular characterization of nucleobase transport by recombinant human and rat equilibrative nucleoside transporters 1 and 2. J. Biol. Chem. 2002, 277, 24938-24948.
17. Buolamwini, J. K. Nucleoside transport inhibitors: Structure-activity relationships and potential therapeutic applications. Curr. Med Chem 1997, 4, 35-66.
18. Young, J. D.; Cheeseman, C. I.; Mackey, J. R.; Cass, C. E.; Baldwin, S. A. Molecular mechanisms of nucleoside and nucleoside drug transport. Curr. Top. Membr. 2000, 50, 329-378.
19. Berens, R. L.; Krug, E. C.; Marr, J. J. In Biochemistry of Parasitic Organisms and Its Molecular Foundations; Marr, J. J., Muller, M., Eds.; Academic Press: London, 1995; pp 89-117.
20. Landfear, S. M. Molecular genetics of nucleoside transporters in Leishmania and African trypanosomes. Biochem. Pharmacol. 2001, 62, 149-155.
21. Fitzgerald, G. A. Dipyridamole. N. Engl. J. Med. 1987, 316, 1247-1257.
22. Van Mouwerik, T. J.; Pangallo, C. A.; Willson, J. K. V.; Fischer, P. H. Augmentation of methotrexate cytotoxicity in human colon cancer cells achieved through inhibition of thymidine salvage by dipyridamole. Biochem. Pharmacol. 1987, 36, 809-814.
23. Curtin, N. J.; Harris, A. L.; Aherne, G. W. Mechanism of cell death following thymidylate synthase inhibition: 2′-deoxyuridine-5′- triphosphate accumulation, DNA damage and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res. 1991, 51, 2346-2352.
24. Smith, P. J.; Marshman, E.; Newell, D. R.; Curtin, N. J. Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport. Br. J. Cancer 2000, 82, 924-930.
25. Turner, R. N.; Aherne, G. W.; Curtin, N. J. Selective potentiation of lomotrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage. Br. J. Cancer 1997, 76, 1300-1307.
26. Marshman, E.; Newell, D. R.; Calvert, A. H.; Dickinson, A. M.; Patel, H. R. H.; Campbell, F. C.; Curtin, N. J. Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro. Clin. Cancer Res. 1998, 11, 2895-2902.
27. Schmoll, H.-J.; Harstrick, A.; Köhne-Wömpner, C.-H.; Schober, C.; Wilke, H.; Poliwoda, H. Modulation of cytotoxic drug activity by dipyridamole. Cancer Treat. Rev. 1990, 17 (Suppl. A), 57-65.
28. Marman, M.; Chan, T. C. K.; Cleary, S.; Howell, S. B. Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartate and dipyridamole. Cancer Chemother. Pharmacol. 1987, 19, 80-83.
29. Wilson, J. K. V.; Fischer, P. H.; Tutsch, K.; Alberti, D.; Simon, K.; Hamilton, R. D.; Bruggink, J.; Koeller, J. M.; Tormey, D. C.; Earhart, R. H.; Ranhosky, A.; Trump, D. L. Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. Cancer Res. 1988, 48, 5585-5590.
30. Higano, C. S.; Livingston, R. B. Oral dipyridamole and methotrexate in solid human tumors: a toxicity trial. Cancer Chemother. Pharmacol. 1989, 23, 259-262.
31. Wilson, J. K. V.; Fischer, P. H.; Remick, S. C.; Tutsch, K. D.; Grem, J. L.; Nieting, L.; Alberti, D.; Bruggink, J.; Trump, D. L. Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans. Cancer Res. 1989, 49, 1866-1870.
32. Budd, G. T.; Jayaraj, A.; Grabowski, D.; Adelstein, D.; Bauer, L.; Boyett, J.; Bukowski, R.; Murthy, S.; Weick, J. Phase I trial of dipyridamole with 5-fluorouracil and folinic acid. Cancer Res. 1990, 50, 7206-7211.
33. Remick, S. C.; Grem, J. L.; Fischer, P. H.; Tutsch, K. D.; Alberti, D. B.; Nieting, L. M.; Tombes, M. B.; Bruggink, J.; Willson, J. K. V.; Trump, D. L. Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion. Cancer Res. 1990, 50, 2667-2672.
34. Mahoney, C.; Wolfram, K. M.; Cocetto, D. M.; Bjornsson, T. D. Dipyridamole kinetics. Clin. Pharmacol Ther. 1982, 31, 330-338.
35. Hollinshead, A. C.; Chuang, C.-Y. Evaluation of the relationships of prealbumin components in sera of patients with cancer. Natl. Cancer Inst. Monogr. 1978, 49, 187-192.
36. 1-acid glycoprotein: reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamole. Biochem. Pharmacol. 1989, 38, 3281-3288.
37. 1-acid glycoprotein (AGP). Bioorg. Med. Chem. Lett. 2001, 7, 2105-2113.
38. Thomae, K. G. British Patent 807826, 1959 (Chem. Abstr. 1959, 53, 12317e). Thomae, K. G. German Patent 1151806, 1963. (Chem. Abstr. 1964, 60, 2974a).
39. Thomae, K. G. British Patent 807826, 1959 (Chem. Abstr. 1959, 53, 12317e). Thomae, K. G. German Patent 1151806, 1963. (Chem. Abstr. 1964, 60, 2974a).
40. Northen, J. S.; Boyle, F. T.; Clegg, W.; Curtin, N. J.; Edwards, A. J.; Griffin, R. J.; Golding, B. T. Controlled Stepwise Conversion of 2,4,6,8-Tetrachloropyrimido[5,4-d]pyrimidine into 2,4,6,8-Tetrasubstituted Pyrimido[5,4-d]pyrimidines. J. Chem. Soc., Perkin Trans. 1 2002, 108-115.
41. McDougal, P. G.; Rico, J. G.; Oh, Y. I.; Condon, B. D. A convenient procedure for the monosilylation of symmetric 1,n-diols. J. Org. Chem. 1986, 51, 3388-3390.
42. Sousa, J. A.; Bluhm, A. L. The reductive cleavage of ozonides to alcohols. J. Org. Chem. 1960, 25, 108-111.
43. Oikawa, Y.; Tanaka, T.; Horita, K.; Yoshioka, T.; Yonemitsu, O. DMPM (3,4-dimethoxybenzyl) protecting group for hydroxy function more readily removable than MPM (p-methoxybenzyl) protecting group by DDQ oxidation. Tetrahedron Lett. 1984, 25, 5393-5396.
44. Horita, K.; Yoshioka, T.; Tanaka, T.; Oikawa, Y.; Yonemitsu, O. On the selectivity of deprotection of benzyl, MPM (4-methoxybenzyl) and DMPM (3,4-dimethoxybenzyl) protecting groups for hydroxy functions. Tetrahedron 1986, 42, 3021-3028.
45. 1-acid glycoprotein binding. Br. J. Cancer 1999, 80, 1738-1746.